feasibility and safety of directly transferring genes into humans, a clinical study was performed. The gene encoding a foreign major histocompatibility complex protein, HLA-B7, was introduced into HLA-B7-negative patients with advanced melanoma by injection of DNA4iposome complexes in an effort to demonstrate gene transfer, document recombinant gene expression, and determine the safety and potential toxicity of this therapy. Six courses of treatment were completed without complications in five HLA-B7-negative patients with stage IV melanoma. Plasmid DNA was detected within biopsies of treated tumor nodules 3-7 days after injection but was not found in the serum at any time by using the polymerase chain reaction. Recombinant HLA-B7 protein was demonstrated in tumor biopsy tissue in all five patients by immunochemistry, and immune responses to HLA-B7 and autologous tumors could be detected. No antibodies to DNA were detected in any patient. One patient demonstrated regression of injected nodules on two independent treatments, which was accompanied by regression at distant sites. These studies demonstrate the feasibility, safety, and therapeutic potential of direct gene transfer in humans.
We have developed a protocol which relies upon the direct transmission of recombinant genes into established tumors in vivo to genetically modify them as they grow in situ. In murine models, introduction of a gene encoding a foreign major histocompatibility complex (MHC) protein (class I) in vivo signals the immune system to respond to the foreign antigen (1, 2) . More importantly, when this gene is transduced into established tumors in vivo, a cytolytic T-cell response is also generated against unmodified tumor cells by increasing the efficacy of the local immune response. This approach has led to significant reductions in tumor growth and, in some cases, complete remission in mice (2) . Based A cutaneous tumor nodule was identified for treatment, and its borders were measured. Control (untreated) nodules were quantitated by computerized tomography immediately prior to the procedure. At each treatment, group I (n = 3) received one injection of -0.2 ml of DNA-liposome complex (0.29 ug of DNA) into the tumor (cumulative dose, 0.86 pg), and group II (n = 3) received three injections (0.2 ml each) at one session within the same nodule (cumulative dose, 2.58 pg). All patients received a total of three treatments with a 2-week interval between treatments. Patient 3 received three courses of treatment (group I, group II, and pulmonary catheterization), with an interval of 9 weeks between group I and II.
Vector Production and Analysis. A eukaryotic expression vector plasmid, pHLA-B7, was prepared by insertion of an HLA-B7 cDNA into the Rous sarcoma virus (RSV)-p-globin plasmid (1, 5 Analysis of HLA-B7 Gene Expression. To confirm recombinant HLA-B7 gene expression within treated tumor nodules, core needle biopsy samples of the injected tumor were obtained 3-7 days after gene transfer. Genomic DNA was isolated from biopsy material (1) , and PCR for the HLA-B7 gene was performed (7, 8) with the primers 5'-AGT-GCC-CAG-GGC-TCT-GAT-GTG-TCT-CTC-ACA-3' (sense; HLA-B7) and 5'-ACC-ACA-GAA-GTA-AGG-TTC-CTT-CAC-AAA-GAT-3' (antisense; simian virus 40 polyadenylylation signal) to generate a 301-bp fragment ( For the RNA analysis, these primers were used after reverse transcription with oligo(dT). For analysis ofplasmid in blood, a different set ofprimers was used, 5'-CTA-CGT-GGA-CGA-CAC-CCA-GTT-CGT-G-3' (sense) and 5'-AGG-GTG-GCC-TCA-TGG-TCA-GAG-ATG-G-3' (antisense), yielding a 525-bp fragment (Fig. 1B) . RNA was analyzed by PCR after DNase digestion and incubation with reverse transcriptase as described (9) . Southern blot hybridization of PCR products from the DNA and RNA analysis ( Fig. 1 A and C) was performed with a probe to internal sequence, derived by digestion of pHLA-B7, described above, with Pvu II and Bgl II by standard methods (8) . The control using human embryonic kidney 293 cells transfected with plasmids in vitro served to establish the conditions for DNase digestion (Fig. 1B) . Under these conditions, no PCR signal was detected in the absence of reverse transcription. Immunologic Analysis. Limiting dilution analysis of the HLA-B7 cytolytic T-lymphocyte (CTL) response was performed by a modification from a previous protocol (10) comparing autologous Epstein-Barr virus-transformed B cells to a subline transduced with an HLA-B7 retroviral vector (1) . CTL function against melanoma cells was assayed as described (11) .
RESULTS
Five patients who satisfied the entry criteria (3) Proc. Natl. Acad Sci. USA 90 (1993) Proc. Natl. Acad. Sci. USA 90 (1993) 11309 Medical Center from June 4, 1992 to February 11, 1993. Clinical profiles of these patients are presented in Table 1 . In each case, these patients suffering from melanoma exhibited progressive disease (stage IV) unresponsive to all conventional forms of therapy. Each patient tolerated the treatment well with no acute complications.
A sample ofthe treated tumor nodules was obtained by a core needle biopsy 3-7 days following the intratumoral injection with HLA-B7 DNA-liposome complexes. This tissue was analyzed for the presence of plasmid DNA, mRNA coding for HLA-B7, and the expression of HLA-B7 protein. In four offive patients, pHLA-B7 DNA was detected within the injected nodule (Fig.  1A) . Blood samples obtained immediately before and multiple times after injection were analyzed for the presence of plasmid DNA by PCR. In the five patients, plasmid DNA was not detected at any time in the blood following gene transfer by PCR (Fig. 1B ; sensitivity, <2 pg/ml).
To determine whether the recombinant HLA-B7 gene was expressed in transduced tumors, mRNA was analyzed. In four of five tumor biopsies, RNA coding for HLA-B7 was detected by PCR after incubation with reverse transcriptase but not in its absence (Fig. 1C) , suggesting that RNA encoding the gene product was synthesized in vivo. In the single case where mRNA was not detected (patient 5), an inhibitor of the PCR was present (data not shown), as was observed in the DNA PCR in this patient (Fig. 1A) .
HLA-B7 protein expression was confirmed within these biopsy samples by immunochemical staining of the samples with monoclonal antibody against this gene product (Fig. 2) or by indirect immunofluorescence of dissociated tumor cells (Fig. 2 legend; data not shown). In all cases, the recombinant protein was detected by these methods at frequencies ranging from 1-10% oftumor cells near the site ofinjection ( Fig. 2 and  legend) . These data also confirmed that the failure to detect DNA and RNA in patient 5 was technical, related to inhibition of the PCR, since HLA-B7 was immunohistochemically detected in tumor cells of this patient.
Analysis of serum biochemical parameters revealed no pattern of systemic abnormalities in these patients, whether DNA was injected intratumorally or by catheter, including serum markers of liver, renal, pancreatic, and cardiac function (data are available upon request). No changes from baseline in any of the serum biochemical parameters were found in the acute period, days 3-7. Myocardial abnormalities were not detected by analysis of creatine kinase or its isoenzymes in the serum of treated patients (data are available upon request), and no electrocardiographic changes or arrhythmias were noted.
A major question regarding the future potential of this gene-delivery approach was whether an immune response would be generated to DNA. Such a response or the formation of antibodies to DNA could induce resistance to treatment or signal the development of autoimmunity. In this study, no increases in anti-DNA antibodies were (12) . Additional monoclonal antibodies used to human HLA-B7 were ME-1 (13) and MB 4.0.2. Immunostaining was performed using a horseradish peroxidase-coupled rabbit anti-mouse second antibody (Vector Cloning Systems) (1). Samples were analyzed in some cases by immunofluorescence with the BB7.1 monoclonal antibody (14) . Indirect immunofluorescent staining of mechanically dispersed unfixed cells was evaluated in patients 1, 2, 3A, and 3B and revealed a frequency of positive cells of -l% for patients 1 and 2 and 1-10%o for patient 3, treatments A and B, in the biopsy sample. quest). These data suggest that DNA is not highly immunogenic in vivo and that the immune response is unlikely to limit in vivo gene transfer by DNA-liposome complexes or other forms of DNA.
Evaluation of the cell-mediated immune response in patient 1 revealed a 5-fold increase in the frequency of HLA-B7-reactive CTL precursors after treatment (Fig. 3A) . The immune response to autologous tumor was also evaluated in two patients where cell lines could be established from the tumor. Tumor-specific CTLs were detected after treatment in both cases, either from tumor-infiltrating lymphocytes (patient 1) or from peripheral blood lymphocytes (patient 3), each of which lysed autologous melanoma specifically in a dose-dependent fashion (Fig. 3 B and C) . These responses to autologous tumor cannot be unequivocally attributed to the gene-transfer treatment; however, the ability to detect T cells specific for melanoma in the peripheral blood (patient 3) is unusual and likely to be treatment-related. This finding, taken together with the increased CTL precursor frequency for HLA-B7, suggests that expression of a foreign MHC gene after direct gene transfer altered the reactivity of the immune system in these patients. Significance (P < 0.05) was assessed by x2 minimization. (B and C) Dose-response analysis of CTL activity from patients 1 and 3 tested against melanoma target cells derived from patient 1 (B) or patient 3 (C) is shown at the indicated effector/target (E:T) ratios. To verify the specificity of this response and to show that these tumor targets were equally susceptible to lysis, lymphokine-activated killer cells were generated separately in the presence of interleukin 2 (1000 units/ml). Lymphokine-activated killer activity (percent specific lysis) against melanoma for patient 1 (B) was 1%, 28%, and 58%, and for patient 3 (C) was 12%, 68%, and 96%, at effector/target ratios of 1:1, 10:1, and 50:1, respectively. (D) Tumor regression in patient 3 at the site of injection and at a distal site is shown. Photographs show a treated nodule (no. 1) and untreated nodules (nos. 2 and 3) at the indicated times after the beginning of treatment 1 in patient 3A. Treatment 1 consisted of single injections at 2-week intervals (three times) in nodule 1. (E) Computerized tomographic evidence of tumor regression at a distant pulmonary site is indicated, showing a responsive pulmonary nodule at the indicated times after treatment 1 began. (F) Photographs of nodule 2 days before (Left) or 60 days after (Right) initiation of treatment 2 (patient 3B). Treatment 2 consisted of three injections into nodule 2 at 2-week intervals (three times) and was begun 85 days after the initiation of treatment 1. With regard to tumor growth, one patient receiving treatment to a cutaneous nodule (patient 3A) showed complete regression of a treated nodule (Fig. 3D) . In this patient, metastatic lesions at distant sites displayed complete regression over the same time period, including a 3-cm pulmonary nodule (Fig. 3E) , a 0.5 x 0.5-cm lesion on the lower back, a 1 x 1-cm lesion on the upper back, a 1 x 1-cm lesion on the skin of the upper arm, and a 1 x 1-cm lesion on the skin of the abdomen. In the same patient, at least one distant site showed no response to DNA-liposome treatment, indicating a mixed response; however, this unresponsive distant site in the lung was documented later to be a second primary cancer, adenocarcinoma. In addition, an independent treatment of a second site resulted in a reduction in tumor size (Fig. 3F) . These data suggest that introduction of the HLA-B7 gene may potentially lead to a therapeutic effect at the treatment site and at distant sites of disease. (25, 26) .
DISCUSSION
In this study, it is postulated that expression of HLA-B7 in tumor cells caused recognition of the foreign transplantation antigen by the immune system, stimulating the release of cytokines locally which induce a T-cell response against the unmodified tumor (2). In murine models, such local immune stimulation enhances recognition oftumor antigens previously undetected by the immune system and induces tumor lysis by CTLs (2) . One patient responded to this treatment on two occasions, with both local and distant tumor regression. Of note, this patient failed to respond to previous immunotherapy with bacillus Calmette-Gudrin and interleukin 2 ( Table 1 legend), which predated gene transfer by 11 months. Although this response was encouraging, we caution that it is not possible at this stage to conclude that the treatment is consistently therapeutic: additional clinical studies will be required to define its efficacy. It is interesting to note that the patient whose tumors regressed after treatment received injections in cutaneous nodules, whereas in the other patients, metastatic lymph nodes were treated (Table 1) . Possibly, lymph node replacement by tumor is associated with a greater degree of immunosuppression, or dermal dendritic cells may provide more efficient antigen presentation and immune stimulation.
Although modified viruses have served as vectors essential for ex vivo gene transfer, their ability to recombine or interact with endogenous viruses has raised concerns regarding their safety for in vivo gene transfer. Nonviral vectors provide an important and potentially safer alternative. Nonviral vectors include DNA-liposome complexes, which can mediate gene transfer into tissues and facilitate uptake by cells in vivo (27, 28) . Plasmid DNA containing appropriate regulatory sequences can be utilized to express a variety of different gene products. Both DNA and liposomes may be stored stably for months, and the use of liposomes obviates the need to synthesize viral vectors, establish subclones of producer cell lines, and assess viral titers and the presence of replicationcompetent helper virus. Plasmid DNA complexed to liposomes has now been employed to transfer genes by injection or catheter into tissues where they stimulate localized biological responses (1, 2, 8, 27, (29) (30) (31) .
The findings reported here represent a requisite step in the development of direct gene transfer for treatment of human disease. These studies demonstrate that a recombinant gene can be directly introduced into humans in vivo and that the gene product is expressed by host cells. The treatment is safe, and no toxicities were observed. The next steps will be to analyze the mechanism of the antitumor response and to improve its efficacy. Now that the safety ofthis approach has been determined, it is possible to include other genes in addition to MHC genes directed at other molecular targets. For example, such genes might include those coding for cytokines, antioncoproteins, growth factor antagonists, or inhibitors of angiogenesis. Alternatively, gene-transfer approaches could be used in combination with existing treatments such as cytokines or adoptive T-cell therapy. The findings reported here suggest that direct gene transfer warrants further development and is likely to contribute to the treatment of cancer and other human diseases.
